相似文献
1
Rituximab use in late antibody-mediated rejection.
Indian J Nephrol. 2016 Sep;26(5):315-316. doi: 10.4103/0971-4065.179305.
2
Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
Exp Clin Transplant. 2017 Feb;15(Suppl 1):150-155. doi: 10.6002/ect.mesot2016.P32.
3
Rituximab-Related Late-Onset Neutropenia in Kidney Transplant Recipients Treated for Antibody-Mediated Acute Rejection.
Exp Clin Transplant. 2017 Aug;15(4):414-419. doi: 10.6002/ect.2016.0027. Epub 2016 Oct 31.
4
Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience.
Indian J Nephrol. 2016 Sep;26(5):317-321. doi: 10.4103/0971-4065.177207.
5
Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation.
Gen Thorac Cardiovasc Surg. 2020 Feb;68(2):142-149. doi: 10.1007/s11748-019-01189-1. Epub 2019 Aug 21.
6
Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
Int J Urol. 2019 Dec;26(12):1114-1120. doi: 10.1111/iju.14108. Epub 2019 Sep 14.
7
Rituximab Therapy for Rejection in Pediatric Heart Transplant.
Exp Clin Transplant. 2018 Apr;16(2):199-203. doi: 10.6002/ect.2015.0370. Epub 2016 May 17.
8
Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
Exp Clin Transplant. 2013 Oct;11(5):404-7. doi: 10.6002/ect.2012.0242.
9
The therapeutic challenge of late antibody-mediated kidney allograft rejection.
Transpl Int. 2019 Aug;32(8):775-788. doi: 10.1111/tri.13436. Epub 2019 May 7.
10
Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Exp Clin Transplant. 2019 Jan;17(Suppl 1):105-109. doi: 10.6002/ect.MESOT2018.O43.
引用本文的文献
1
Rituximab in kidney disease and transplant.
Animal Model Exp Med. 2019 Mar 26;2(2):76-82. doi: 10.1002/ame2.12064. eCollection 2019 Jun.
2
Acute rejection.
J Thorac Dis. 2017 Dec;9(12):5440-5457. doi: 10.21037/jtd.2017.11.83.
本文引用的文献
1
Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience.
Indian J Nephrol. 2016 Sep;26(5):317-321. doi: 10.4103/0971-4065.177207.
2
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
Transplantation. 2016 Feb;100(2):391-9. doi: 10.1097/TP.0000000000000958.
3
Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Transplantation. 2015 Jan;99(1):56-62. doi: 10.1097/TP.0000000000000244.
4
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Transplantation. 2014 Jun 27;97(12):1240-6. doi: 10.1097/01.TP.0000442503.85766.91.
5
Targeting B cells and antibody in transplantation.
Am J Transplant. 2011 Jul;11(7):1359-67. doi: 10.1111/j.1600-6143.2011.03554.x. Epub 2011 Jun 10.
6
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.
Am J Transplant. 2009 Nov;9(11):2520-31. doi: 10.1111/j.1600-6143.2009.02799.x.
7
Rituximab for humoral rejection after kidney transplantation: an update.
Transplantation. 2009 Apr 27;87(8):1261. doi: 10.1097/TP.0b013e31819f627a.
8
Impact of rituximab therapy for treatment of acute humoral rejection.
Clin Transplant. 2009 Jan-Feb;23(1):63-73. doi: 10.1111/j.1399-0012.2008.00902.x.
9
Rituximab as treatment for refractory kidney transplant rejection.
Am J Transplant. 2004 Jun;4(6):996-1001. doi: 10.1111/j.1600-6143.2004.00454.x.
Zotero 插件